Skip to content

US · RMD · MEDICAL - DEVICES

ResMed Inc. (RMD) intrinsic value and stock valuation

$235.63as of 2026-11-21 · Mkt cap 32.5B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

ResMed Inc. DCF and intrinsic value

InvestorsCraft values RMD with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from RMD’s statements →

ResMed Inc. Graham Number

Graham Number: $93.48d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Devices San Diego, CA 92123 resmed.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$5.15B+11.7% 5y CAGRd
20112025
Net income
$1.4B+17.6% 5y CAGRd
20112025
Free cash flow
$1.65B+21.6% 5y CAGRd
20122026
Total equity
$5.97B+19% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20262025202420232022
Revenue—$5.15B$4.69B$4.22B$3.58B
Operating income—$1.69B$1.32B$1.13B$1B
Net income—$1.4B$1.02B$897.6M$779.4M
EPSd—$9.51M$6.92M$6.09M$5.3M
Operating cash flow$1.81B$1.75B$1.4B$693.3M$351.2M
Capital expenditure-$-156.28M-$-89.86M-$-114.86M-$-134M-$-156.04M
Free cash flow$1.65B$1.66B$1.29B$559.3M$195.1M
Total assets—$8.17B$6.87B$6.75B$5.1B
Total debt—$851.8M$873.9M$1.58B$917.6M
Net debt—-$-357.64M$635.6M$1.35B$643.8M
Total equity—$5.97B$4.86B$4.13B$3.36B
Cash and short-term investments—$1.21B$238.4M$227.9M$273.7M
Income statement
20252024202320222021
Revenue$5.15B$4.69B$4.22B$3.58B$3.2B
Cost of revenue$2.09B$2.03B$1.87B$1.55B$1.36B
Gross profit$3.05B$2.66B$2.36B$2.02B$1.84B
Research and development expenses$331.3M$307.5M$287.6M$253.6M$225.3M
Selling, general and administrative expenses$991M$917.1M$874M$739.4M$670.4M
Other expenses$47.3M$110.8M$62.2M$31.1M$39.8M
Operating expenses$1.37B$1.34B$1.22B$1.02B$935.4M
Cost and expenses$3.46B$3.37B$3.09B$2.58B$2.29B
Interest income$0.00$0.00$0.00$0.00$360K
Interest expense$12.6M$45.7M$47.4M$22.3M$24M
Depreciation and amortization$235.8M$216.2M$196.5M$193.8M$191.5M
Ebitda$1.91B$1.53B$1.36B$1.18B$1.1B
Operating income$1.69B$1.32B$1.13B$1B$903.7M
Total other income/expenses, net-$-7.8M-$-55.09M-$-30.21M-$-39.8M-$-20.02M
Income before tax$1.68B$1.26B$1.1B$960.5M$883.7M
Income tax expense$276.8M$243.9M$204.1M$181.1M$409.2M
Net income$1.4B$1.02B$897.6M$779.4M$474.5M
Weighted average shares outstanding$146.7M$147M$146.8M$146.1M$145.3M
Weighted average diluted shares outstanding$147.3M$147.6M$147.5M$147M$146.5M
Balance sheet
20252024202320222021
Cash and short-term investments$1.21B$238.4M$227.9M$273.7M$295.3M
Net receivables$990.7M$837.3M$704.9M$576M$625.2M
Inventory$927.7M$822.3M$998M$743.9M$457M
Total current assets$3.51B$2.36B$2.37B$1.93B$1.57B
Property, plant and equipment, net$718.3M$699.2M$665.8M$630.5M$592.1M
Goodwill and intangible assets$3.51B$3.33B$3.32B$2.28B$2.32B
Long-term investments$85M$169.8M$156.9M$67.2M$75.5M
Total non-current assets$4.67B$4.51B$4.38B$3.16B$3.15B
Total assets$8.17B$6.87B$6.75B$5.1B$4.73B
Accounts payable$278.2M$237.7M$150.8M$159.3M$138M
Short-term debt$40.4M$35.2M$31.8M$31.8M$35.6M
Deferred revenue$166M$152.6M$138.1M$108.7M$109.6M
Total current liabilities$1.02B$910.7M$758.5M$689.3M$911.8M
Long-term debt$811.4M$838.8M$1.55B$885.8M$758.1M
Deferred revenue, non-current$156.8M$137.3M$119.2M$95.5M$91.5M
Total non-current liabilities$1.19B$1.1B$1.86B$1.05B$930.7M
Capital lease obligations$183.5M$166.7M$138.8M$142.3M$138.4M
Total liabilities$2.21B$2.01B$2.62B$1.74B$1.84B
Common stock$760K$590K$590K$590K$580K
Retained earnings$6.08B$4.99B$4.25B$3.61B$3.08B
Accumulated other comprehensive income (loss)-$-74.7M-$-251.53M-$-272.53M-$-312.75M-$-193.49M
Total equity$5.97B$4.86B$4.13B$3.36B$2.89B
Total investments$85M$169.8M$156.9M$67.2M$75.5M
Total debt$851.8M$873.9M$1.58B$917.6M$793.7M
Net debt-$-357.64M$635.6M$1.35B$643.8M$498.4M
Cash flow statement
20262025202420232022
Net income$1.52B$1.4B$1.02B$897.6M$779.4M
Depreciation and amortization$244.2M$235.8M$216.2M$197.6M$193.8M
Stock-based compensation$104.4M$91.7M$80.2M$71.1M$65.3M
Change in working capital-$-74.24M$16.7M$44.8M-$-462.13M-$-708.08M
Accounts receivable-$-96.78M-$-76.68M-$-134.28M-$-106.51M$19.4M
Inventory-$-9.92M-$-80.17M$172.2M-$-248.83M-$-311.68M
Accounts payable$172.7M$91M$0.00$31.3M-$-247.63M
Net cash provided by operating activities$1.81B$1.75B$1.4B$693.3M$351.2M
Investments in property, plant and equipment-$-156.28M-$-89.86M-$-99.46M-$-134M-$-156.04M
Acquisitions, net-$-350.72M-$-139.25M-$-133.46M-$-1.01B-$-42.78M
Net cash used for investing activities-$-545.2M-$-200.04M-$-269.78M-$-1.16B-$-229.92M
Common stock issued$74.5M$74.4M$53.1M$49.1M$47.4M
Common stock repurchased-$-700.04M-$-300.02M-$-150.01M$0.00$0.00
Dividends paid-$-349.66M-$-310.88M-$-282.32M-$-258.28M-$-245.34M
Net cash used for financing activities-$-1.01B-$-606.25M-$-1.12B$422.9M-$-128.36M
Net change in cash$259.8M$971.1M$10.5M-$-45.82M-$-21.57M
Cash at end of period$1.47B$1.21B$238.4M$227.9M$273.7M
Operating cash flow$1.81B$1.75B$1.4B$693.3M$351.2M
Capital expenditure-$-156.28M-$-89.86M-$-114.86M-$-134M-$-156.04M
Free cash flow$1.65B$1.66B$1.29B$559.3M$195.1M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About ResMed Inc.

        ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.

        CEO
        Michael J. Farrell
        Employees
        10.6K
        Beta
        0.78

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of ResMed Inc. (RMD)?

        ResMed Inc. (RMD) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is RMD undervalued?

        RMD trades at a price of $235.63 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.